Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Semi-annual Business Results
December 22, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
December 22, 2003
- NEW PRODUCTS
December 22, 2003
- Virtual Heart Should Improve Drug Development Success Rates: Dr Noble
December 22, 2003
- REGULATORY NEWS IN BRIEF
December 15, 2003
- Taisho, HP Japan Create First PMS Support System for OTC Drugs
December 15, 2003
- Approval of 3 New Drugs Incl. Olmes Recommended
December 15, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 15, 2003
- Semi-annual Business Results
December 15, 2003
- Semi-annual Business Results
December 15, 2003
- Kraft: Double-digit Growth in Sales, Profits
December 15, 2003
- VITAL-NET: Sales Price Reductions Hurt Profits
December 15, 2003
- Cawachi: Operating Profits Up 0.8%
December 15, 2003
- Atol: Sales, Profits Down
December 15, 2003
- Yomeishu: Sales Slip 5.4%
December 15, 2003
- Ohki: Consolidated Sales Grow 8.2%
December 15, 2003
- OTC NEWS IN BRIEF
December 15, 2003
- Ando Chemical Works: Sales Down 8.2% to \12.4 Bil.
December 15, 2003
- GSK Completes PI Study on Ono's New HIV Drug in the US
December 15, 2003
- Nippon Chemiphar: Drug Sales Fall 9.9% to \7,738 Mil.
December 15, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…